We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , BioNTech (BNTX - Free Report) , Moderna (MRNA - Free Report) and Novavax (NVAX - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
FDA Approves Pfizer, Moderna's New Covid Vaccines
The FDA approved Pfizer/BioNTech and Moderna’s updated mRNA vaccines to protect against the currently circulating strains of the COVID-19 virus.
Moderna and Pfizer’s updated mRNA vaccines are each approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
Pre-clinical/clinical data from studies on Moderna and Pfizer’s updated mRNA vaccines have shown improved neutralizing antibody responses against multiple circulating Omicron-related sub-lineages, including XBB.1.5, BA.2.86 (also called Pirola) and EG.5.1 (also called Eris).
Moderna and Pfizer’s mRNA vaccines have been updated to include a single component that corresponds to the Omicron variant XBB.1.5, as directed by the FDA in June. In the said month, XBB.1.5, a subvariant of Omicron, was the dominant variant. Now, the dominant strains are Pirola and Eris. However, the companies are confident that their updated vaccines can provide protection against Pirola and Eris, which closely match the XBB.1.5 subvariant.
Infection rates are once again climbing in the United States, with Pirola and Eris accounting for the majority of the cases.
Moderna and Pfizer have been manufacturing the updated vaccines at risk and believe they will be ready for commercial delivery of the updated vaccines for the 2023-2024 fall and winter season.
They expect the vaccines to be launched in pharmacies, hospitals and clinics across the United States once the U.S. Centers for Disease Control and Prevention (CDC) recommends the jab. The CDC’s Advisory Committee on Immunization Practices will meet on Sep 12 to provide recommendations on who should receive an updated vaccine.
Novavax has also developed an updated protein-based non-mRNA COVID-19 vaccine to target XBB lineages. However, the FDA did not give a green signal to Novavax’s updated vaccine. Novavax’s stock was down almost 13% in response.
Novavax issued a press release stating that it is ready to distribute its updated vaccine for the fall season once it receives FDA approval and CDC recommendation.
Drugmakers are trying to promote the idea of people taking an updated COVID shot along with their annual flu vaccination. However, some experts feel the protection offered by these updated shots wanes over time and with a new variant superseding the older one. Sales of Pfizer, Moderna and Novavax suffered in 2022 and the first half of 2023 as demand for COVID vaccines declined. It remains to be seen if these new “boosters” provide some boost to their makers’ top lines.
Pfizer/BioNTech and Moderna’s regulatory filings seeking approval for the updated vaccines are also under review in Europe, with a decision anticipated in the coming weeks.
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax
For Immediate Release
Chicago, IL – September 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , BioNTech (BNTX - Free Report) , Moderna (MRNA - Free Report) and Novavax (NVAX - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
FDA Approves Pfizer, Moderna's New Covid Vaccines
The FDA approved Pfizer/BioNTech and Moderna’s updated mRNA vaccines to protect against the currently circulating strains of the COVID-19 virus.
Moderna and Pfizer’s updated mRNA vaccines are each approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
Pre-clinical/clinical data from studies on Moderna and Pfizer’s updated mRNA vaccines have shown improved neutralizing antibody responses against multiple circulating Omicron-related sub-lineages, including XBB.1.5, BA.2.86 (also called Pirola) and EG.5.1 (also called Eris).
Moderna and Pfizer’s mRNA vaccines have been updated to include a single component that corresponds to the Omicron variant XBB.1.5, as directed by the FDA in June. In the said month, XBB.1.5, a subvariant of Omicron, was the dominant variant. Now, the dominant strains are Pirola and Eris. However, the companies are confident that their updated vaccines can provide protection against Pirola and Eris, which closely match the XBB.1.5 subvariant.
Infection rates are once again climbing in the United States, with Pirola and Eris accounting for the majority of the cases.
Moderna and Pfizer have been manufacturing the updated vaccines at risk and believe they will be ready for commercial delivery of the updated vaccines for the 2023-2024 fall and winter season.
They expect the vaccines to be launched in pharmacies, hospitals and clinics across the United States once the U.S. Centers for Disease Control and Prevention (CDC) recommends the jab. The CDC’s Advisory Committee on Immunization Practices will meet on Sep 12 to provide recommendations on who should receive an updated vaccine.
Novavax has also developed an updated protein-based non-mRNA COVID-19 vaccine to target XBB lineages. However, the FDA did not give a green signal to Novavax’s updated vaccine. Novavax’s stock was down almost 13% in response.
Novavax issued a press release stating that it is ready to distribute its updated vaccine for the fall season once it receives FDA approval and CDC recommendation.
Drugmakers are trying to promote the idea of people taking an updated COVID shot along with their annual flu vaccination. However, some experts feel the protection offered by these updated shots wanes over time and with a new variant superseding the older one. Sales of Pfizer, Moderna and Novavax suffered in 2022 and the first half of 2023 as demand for COVID vaccines declined. It remains to be seen if these new “boosters” provide some boost to their makers’ top lines.
Pfizer/BioNTech and Moderna’s regulatory filings seeking approval for the updated vaccines are also under review in Europe, with a decision anticipated in the coming weeks.
Pfizer and Moderna have a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.